Source: American Society of Clinical Oncology. Conference titles: Annual meeting of the American Society of Clinical Oncology. Unidade: FM
Subjects: NEOPLASIAS MAMÁRIAS, QUIMIOTERAPIA
ABNT
CASTRO, G. et al. Casing a low c-erb-B2 expression after primary chemotherapy (PCT) predicts longer disease-free survival (DFS) in Brazilian patients with primary breast cancer. American Society of Clinical Oncology. Chicago: Faculdade de Medicina, Universidade de São Paulo. . Acesso em: 23 maio 2024. , 2003APA
Castro, G., Diz, M. D. E., Siqueira, S. A. C., Carvalho, F. M., Folgueira, M. A. A. K., Snitcovsky, I. M., et al. (2003). Casing a low c-erb-B2 expression after primary chemotherapy (PCT) predicts longer disease-free survival (DFS) in Brazilian patients with primary breast cancer. American Society of Clinical Oncology. Chicago: Faculdade de Medicina, Universidade de São Paulo.NLM
Castro G, Diz MDE, Siqueira SAC, Carvalho FM, Folgueira MAAK, Snitcovsky IM, Brentani MM, Federico MHH. Casing a low c-erb-B2 expression after primary chemotherapy (PCT) predicts longer disease-free survival (DFS) in Brazilian patients with primary breast cancer. American Society of Clinical Oncology. 2003 ; 22[citado 2024 maio 23 ]Vancouver
Castro G, Diz MDE, Siqueira SAC, Carvalho FM, Folgueira MAAK, Snitcovsky IM, Brentani MM, Federico MHH. Casing a low c-erb-B2 expression after primary chemotherapy (PCT) predicts longer disease-free survival (DFS) in Brazilian patients with primary breast cancer. American Society of Clinical Oncology. 2003 ; 22[citado 2024 maio 23 ]